Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Baxter pays $60mm up front for exclusive rights to CTI's Phase III pacritinib; rights returned

Executive Summary

Baxter International Inc. licensed exclusive rights to develop and sell oncology firm Cell Therapeutics Inc.’s pacritinib, a Phase III JAK2/FLT3 inhibitor for myelofibrosis, leukemia, and solid tumors. The companies will co-promote in the US. CTI originally gained global pacritinib rights from SBIO in April 2012.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Co-Promotion

Related Companies